Premixed glucagon/insulin solution for faster insulin absorption in Type 1 diabetes.

Status

Suspended

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-510408-32-02

Enrollment

Registered

2025-01-23

Start date

2025-04-01

Completion date

Unknown

Last updated

2026-01-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 1 diabetes

Brief summary

The area under the glucose consumption curve and area under the insulin curve for the first 30 minutes.

Detailed description

Area under glucose consumption curve for any other time span during the first 4 hours, Area under insulin curve for any other time span during the first 4 hours, Pharmacokinetic estimates for insulin, Pharmacodynamic estimates for insulin

Interventions

DRUGGLUCAGON

DRUGLyumjev 100 units/mL solution for injection in vial

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Secondary

Measure	Time frame
Area under glucose consumption curve for any other time span during the first 4 hours, Area under insulin curve for any other time span during the first 4 hours, Pharmacokinetic estimates for insulin, Pharmacodynamic estimates for insulin	—

Primary

Measure	Time frame
The area under the glucose consumption curve and area under the insulin curve for the first 30 minutes.	—

Countries

Norway

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026